



cancer conference
ncri
national cancer research institute

4 - 7 October 2009

Programme 2009



Programme

Contents

| | |
|--|-----------|
| Programme at a glance | 3 |
| Symposia in detail The Conference features a number of high-quality symposia, each designed to attract a broad spectrum of cancer specialists. | 10 |
| Parallel sessions in detail The parallel sessions cover a breadth of topics, spanning the central themes of: The cancer cell and model systems; Diagnosis and therapy; Epidemiology and prevention; Information, patients and the public; Survivorship and end-of-life care; and Tumour specific research. | 12 |
| Workshops in detail The Conference also features a range of workshops designed to provide opportunities for development and networking. | 34 |

Programme at a glance **Sunday**

12.15 – 14.15 **The tumour microenvironment and its effect on treatment response**

Hosted by Stephanie McKeown and Tracy Robson

14.20 – 14.30 **Welcome address**

Sir Kenneth Calman

Chair, National Cancer Research Institute, UK

14.30 – 15.10 **Breast cancer as a disease of self-seeding: concept, evidence, and clinical implications**

Larry Norton

Memorial Sloan-Kettering Cancer Center, New York, USA



15.10 – 15.50 **Role of telomeres in cancer and ageing**

Maria Blasco

Spanish National Cancer Research Centre, Madrid, Spain



16.00 – 17.30 Poster Session A and Refreshment Break

17.40 – 18.20 **Drugging the cancer genome: design of personalised cancer medicines**

The BACR Tom Connors Lecture

Paul Workman

Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton, UK



18.30 – 19.30 **Public event and open forum: The Cancer Tales**
Chaired by Sir Kenneth Calman

Chair, National Cancer Research Institute, UK

This performance of two stories from Cancer Tales, written by Nell Dunn, is based on the real-life experiences of cancer patients and their families.

The play will be followed by a questions and answers forum with a panel of experts, and is free for both Conference delegates and the public to attend



19.30 – 21:00 Opening Reception and Trade Exhibition

Programme at a glance **Monday**

08.00 – 08.50

Workshops

- **BACR educational workshop: early phase clinical trial design for non-clinicians**
Hosted by Anne Thomas
University of Leicester, UK
- **BOA 'Meet the Professor' workshop: cell cycle control, mechanisms and their relevance to cancer?**
Hosted by Kai Stoeber
University College London, UK

09.00 – 09.10

Introduction to the programme

Ron Laskey

Chair, Programme Planning Committee, UK

09.10 – 09.50

Synthetic lethal approaches to the development of new therapies for cancer

Alan Ashworth

Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK



09.50 – 10.30

Difficult decisions: end of life care or assisted suicide?

Ilorá Finlay

Cardiff University, UK



10.30 – 11.00

Refreshment Break and Exhibition Viewing

11.00 – 12.30

Symposia

- **Getting personal in anticancer drug development**
Hosted by Johann de Bono
The Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK
- **Societal attitudes to death and dying**
Hosted by Mike Richards¹ and Teresa Tate²
¹National Cancer Director (England), UK, and ²Marie Curie Cancer Care, UK
- **Targeting invasion and metastases**
Hosted by Margaret Frame
University of Edinburgh, UK



12.30 – 14.20

Poster Session B and Lunch

12.30 – 15.30

Trade Exhibition Viewing

13.00 – 14.00

Commercial workshop

- Illumina high throughput sequencing: investigations into cancer genome biology – Sponsored by Illumina
- Emerging treatment options in metastatic disease - Sponsored by Amgen



14.30 – 15.30

Workshops

- How to become a post-doc or a clinician scientist
- Prioritising research in the networks
- Randomised controlled trials in end of life care
- Tumour banking and access to samples debate

15.40 – 17.55

Parallel sessions

- From the genome to the clinic: connecting data for better health
- Hypoxia and the Warburg effect
- Improving patient care: quality assurance of psychological care
- Infection and cancer: epidemiology, biology and prevention
- Lung cancer
- New strategies for improving prognosis in breast cancer
- Paediatric tumours
- PET Imaging
- Proffered paper highlights 1
- Targeting mitosis
- Upper gastrointestinal cancers

18.00 – 18.30

Refreshment Break

18.30 – 19.50

Clinical trials showcase

Hosted by David Cameron

National Cancer Research Network, UK

- **Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer**

Andrew Tutt

Breakthrough Breast Cancer Research Unit, King's College London Guy's Hospital, London, UK

- **MRC OV05/EORTC 55955 Ovarian Cancer Trial of early treatment of relapse based on CA125 level alone versus delayed treatment**

Gordon Rustin

Mount Vernon Cancer Centre, Northwood, UK

- **Results from the MRC Coin trial of first-line therapy for advanced colorectal cancer (aCRC)**

Tim Maughan

Cardiff University, UK

- **Results of a phase III multi-centre randomised controlled trial of intensity modulated (IMRT) vs conventional radiotherapy (RT) in head and neck cancer (PARSPORT: ISRCTN48243537; CRUK/03/005)**

Christopher Nutting

Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, UK

19.50 – 21.00

Drinks Reception

20.00 – 22.30

Chairman's Reception (by invitation)

Programme at a glance **Tuesday**

08.00 – 08.50

Workshops

- BACR educational workshop: how do cells maintain their integrity? An introduction to DNA double strand break repair and its relevance to leukaemia
- BOA Workshop: all about 'omics
- Novel practical designs for clinical trials
- Methodologies in complementary therapy research

09.00 – 09.40

Tumour suppressors and hypoxia pathways in cancer

Peter Ratcliffe

University of Oxford, UK



09.40 – 10.20

Evolution of the cancer clinical trial over three decades: problems of design, analysis, reporting and interpretation

Ian Tannock

Princess Margaret Hospital, Toronto, Canada



10.20 – 11.00

Refreshment Break and Exhibition Viewing

11.00 – 12.30

Symposia

- **30th Anniversary of p53**
Hosted by Karen Vousden
Beatson Institute of Cancer Research,
Glasgow, UK
- **Research priorities from a global perspective**
Hosted by Jack Cuzick
Cancer Research UK Clinical Centre, Barts
and The London, UK
- **Therapeutic antibodies**
Hosted by Martin Glennie
University of Southampton, UK

12.30 – 14.20

Poster Session C and Lunch

12.30 – 15.30

Trade Exhibition Viewing

13.00 – 14.00

Commercial and satellite workshops

- nab™ technology: advancing the treatment of breast cancer
- Improving clinical outcomes: focus on Venous Thromboembolism
- Translating genomic biomarkers to medical advantage: the integrated genomics approach

14.30 – 15.30

Workshops

- The targeted therapies nurses forum
- Data linkage and long-term follow up of clinical trials
- Career paths for post-docs

15.40 – 17.55

Parallel sessions

- Acute leukaemia
- Anti-cancer drug discovery: natural products and rational design
- Colorectal cancer: optimising screening and prevention
- High throughput sequencing and cancer genomes
- Proffered paper highlights 2
- Prostate and bladder cancer
- Radiation oncology
- Research portrayal in the media
- Senescence and autophagy as an approach to therapy
- Survivorship and late effects of treatment

17.55 – 18.25

Refreshment Break

18.30 – 19.10

Complexity of clonal architecture in childhood leukaemia: Darwin re-visited

Mel Greaves

The Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK



19.10 – 19.50

The Bcl-2 family in cancer development and cancer treatment

Suzanne Cory

The Walter and Eliza Hall Institute of Medical Research, University of Melbourne, Australia



20.00 – 23.00

Pfizer/BOA Excellence in Oncology Awards
(by invitation)

20.15 – 01.00

Conference Dinner and Party (ticketed event)

Programme at a glance **Wednesday**

08.30 – 09.30

Breakfast

09.00 – 09.50

The use of biomarkers in cancer clinical trials

Marc Buyse

International Drug Development Institute, Brussels, Belgium



09.50 – 10.10

Refreshment Break

10.10 – 12.25

Parallel sessions

- Brain tumours
- Economics of drug development and provision
- Personalised pathology
- Preclinical models
- Raising awareness and promoting early diagnosis
- Successes from the ECMC Network: early phase trials, biomarkers and imaging
- Symptom management
- Synthetic lethality: targeting damaged pathways
- Tumour stroma and vasculature

12.35 – 13.15

Using mice to model cancer cures

Gerard Evan

UCSF Helen Diller Family Comprehensive Cancer Centre, San Francisco, USA



13.15 – 13.25

Closing comments

Sir Kenneth Calman

Chair, National Cancer Research Institute

13.25 – 14.00

Lunch (available to take away)

Symposia in detail **Monday**

Getting personal in anticancer drug development

Hosted by Johann de Bono

The Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK

- **Johann de Bono**
The Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK
Introduction
- **Stephen Friend**
Sage Bionetworks, USA
The need for diseases models with "commons" as a mean to share data
- **Caroline Dive**
Paterson Institute for Cancer Research, Manchester, UK
Utility of Circulating Tumour Cells (CTCs) in drug development for lung cancer
- **Josep Tabernero**
Vall d'Hebron University Hospital, Barcelona, Spain
Using biomarkers in early stage development

Societal attitudes to death and dying

Hosted by Mike Richards¹ and Teresa Tate²

National Cancer Director (England), UK, and ²Marie Curie Cancer Care, UK

- **Mike Richards¹ and Teresa Tate²**
¹National Cancer Director, UK, and ²Marie Curie Cancer Care, UK
Introduction
- **Allan Kellehear**
University of Bath, UK
Dying old and alone – a preference?
- **Jane Seymour**
University of Nottingham, UK
Public attitudes to death, dying and bereavement: a synthesis of evidence
- **Barbara Monroe**
St. Christopher's Hospice, London, UK
Societal attitudes to death and dying – local engagement projects
- **Mayur Lakhani**
National Council for Palliative Care and the National Coalition on End of Life Care, UK
Making things happen: The work of the National Coalition



Targeting invasion and metastases

Hosted by Margaret Frame

University of Edinburgh, UK

- **Margaret Frame**
University of Edinburgh, UK
Introduction
- **Peter Friedl**
Radboud University, Netherlands
Imaging of the invasive process in real time
- **Valerie Weaver**
University of Pennsylvania, USA
Cell adhesion molecules and tumour dormancy in 3-dimensional systems
- **Jim Norman**
Beatson Institute for Cancer Research, Glasgow, UK
Integrin trafficking in cancer

Symposia in detail **Tuesday**

30th Anniversary of p53

Hosted by Karen Vousden

Beatson Institute of Cancer Research, Glasgow, UK

- **Karen Vousden**
Beatson Institute of Cancer Research, Glasgow, UK
Introduction
- **Karen Vousden**
Beatson Institute of Cancer Research, Glasgow, UK
Regulations and functions of p53
- **David Lane**
University of Dundee, UK
Drug discovery in the p53 pathway
- **Guillermina Lozano**
MD Anderson Center, Houston, USA
The Mdm2/Mdm4 complex: a rheostat for p53 activity

Research priorities from a global perspective

Hosted by Jack Cuzick

Cancer Research UK Clinical Centre, Barts and The London, UK

- **Jack Cuzick**
Cancer Research UK Clinical Centre, Barts and The London, UK
Introduction
- **Eduardo Franco**
McGill University, Montreal, Canada
HPV vaccination and improved screening via molecular methods:
new strategies in cervical cancer prevention
- **Mitch Dowsett**
The Institute of Cancer Research, London, UK
Understanding biological pathways for enhanced treatment and
prevention of breast cancer
- **Peter Boyle**
International Prevention Research Institute, Lyon, France
New initiatives to control tobacco

Therapeutic antibodies

Hosted by Martin Glennie

University of Southampton, UK

- **Martin Glennie**
University of Southampton, UK
Introduction
- **Martin Glennie**
University of Southampton, UK
Selecting targets for anti-cancer antibodies: what have we learnt
so far?
- **Robert Marcus**
King's College Hospital, London, UK
Title to be confirmed
- **James Allison**
Memorial Sloan-Kettering Cancer Center, New York, USA
Checkpoint blockade in tumour immunotherapy: new insights and
opportunities

Parallel sessions in detail **Monday**

From the genome to the clinic: connecting data for better health

Hosted by Sir Alex Markham¹ and Julie Clifton²

¹University of Leeds, UK; and ²NCRI Consumer Liaison Group, UK

- **Sir Alex Markham¹ and Julie Clifton²**

¹University of Leeds, UK; and ²NCRI Consumer Liaison Group, UK

Introduction

- **Eric Holowaty**

Cancer Care, Ontario, Canada

Cancer Registries and the electronic health record

- **Tjeerd van Staa**

General Practice Research Database, UK

Connecting from primary to secondary care: the data experience

- **Stephen Friend**

Sage Bionetworks, USA

Data sharing and health outcomes

Proffered paper presentations:

- **Marketa Zvelebil**

Breakthrough Breast Cancer Research, London, UK

Integration, analysis and meta-mining of data to aid disease diagnosis, prognosis and treatment response

- **Alex Walker**

University of Nottingham, UK

Tricyclic antidepressants protect against glioma and colorectal cancer

- **Thomas Clarke**

University of Leeds, UK

Trends in laparoscopic colorectal tumour resections across England between 1998 and 2006

Hypoxia and the Warburg effect

Hosted by Peter Ratcliffe

University of Oxford, UK

- **Peter Ratcliffe**

University of Oxford, UK

Introduction

- **Jacques Pouyssegur**

Developmental Biology and Cancer Research, Nice, France

Hypoxia and tumour metabolism: approach towards new anti-cancer targets

- **Ian Tomlinson**

University of Oxford, UK

Fumarate hydratase and other genetic insights into tumour metabolism

- **Gregg Semenza**

Johns Hopkins University School of Medicine, USA

Regulation of glucose and energy metabolism by Hypoxia-Inducible Factor 1

Proffered paper presentations:

- **Christopher Ricketts**

University of Oxford, UK Renal Molecular Oncology Group, Medical & Molecular Genetics, University of Birmingham, UK

Genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD

- **Brijesh Madhok**
University of Leeds, UK
Inhibition of pyruvate dehydrogenase kinase activity promotes apoptosis in colorectal cancer cells
- **Sashidar Yeluri**
Leeds Institute of Molecular Medicine, University of Leeds & St James's University Hospital, UK
Lactase dehydrogenase-5 is an independent prognostic factor in colorectal cancer: implication for future therapies

Improving patient care: quality assurance of psychological care

Hosted by Michael Sharpe

University of Edinburgh, UK

- **Michael Sharpe**
University of Edinburgh, UK
Introduction
- **Jane Walker**
University of Edinburgh, UK
SMaRT quality assurance: making sure the treatment given is the treatment intended
- **Amanda Ramirez**
Guy's, King's and St Thomas' School of Medicine, London, UK
Maintaining the quality of a complex behavioural intervention to promote early presentation of cancer in a randomised controlled trial
- **John Norrie**
Robertson Centre for Biostatistics, University of Glasgow, UK
'Quality' issues in complex intervention randomised controlled trials

Proffered paper presentations:

- **Caroline Burgess**
Institute of Psychiatry/King's College London, London, UK
Training health professionals to deliver an intervention to promote early presentation of breast cancer: a pilot study in the NHS Breast Screening Programme
- **Eleanor Mann**
Kings College London, UK
Cognitive behaviour therapy for menopausal symptoms following breast cancer treatment
- **Galina Velikova**
University of Leeds, UK
Patients report improvements in continuity of care when quality of life assessments are used routinely in oncology practice: secondary outcomes of a randomised controlled trial

Infection and cancer: epidemiology, biology and prevention

Hosted by Lawrence Young

University of Birmingham, UK

- **Lawrence Young**
University of Birmingham, UK
Introduction
- **Charles Rabkin**
National Cancer Institute, USA
Molecular epidemiology of infection-related cancer
- **Thomas Schulz**
Hannover Medical School, Germany
Role of KSHV infection in the pathogenesis of sarcoma and lymphoma
- **Jean Crabtree**
Leeds Institute for Molecular Medicine, University of Leeds, UK
Helicobacter pylori infection and gastric cancer: from cause to cure

Proffered paper presentations:

- **Simon Chanas**
University of Birmingham, UK
Merkel cell polyomavirus in Merkel carcinoma: pilot project to develop biomarkers for validation in a subsequent clinical trial
- **Farhad Mashayekhi**
University of Guilan, Rasht, Iran, Islamic Republic of
Association of *Helicobacter pylori* vacA genotype with gastric cancer in northern Iran
- **Richard Shaw**
University of Liverpool, UK
Host-viral epigenetic interactions in HPV16-mediated oropharyngeal cancer

Lung cancer

Hosted by Michael Cullen

Queen Elizabeth Hospital, Birmingham, UK

- **Michael Cullen**
Queen Elizabeth Hospital, Birmingham, UK
Introduction
- **Aman S Coonar**
Papworth Hospital, Cambridge, UK
Video-assisted thoracic surgery and its place in lung cancer management
- **Frances Shepherd**
Princess Margaret Hospital, Toronto, Canada
Targeted therapy for advanced NSCLC: two steps forward and one step back?
- **Jean-Charles Soria**
Institut de Cancérologie Gustave Roussy, Paris, France
Biomarkers and the future of chemotherapy in non-small cell lung cancer

Proffered paper presentations:

- **Linda Sharp**
National Cancer Registry Ireland, Cork, Ireland
The financial costs and consequences of cancer for patients and their families: a postal survey of patients with breast, lung, and prostate cancer in Ireland

- **Henrik Møller**
King's College London, UK
Intensity of radical resection for lung cancer in relation to survival outcomes in England
- **Alex Chacko**
Queen's University Belfast, UK
The mitochondrial ATP transporter VDAC1 /Porin is required for TRAIL-induced apoptosis in non-small cell lung cancer

New strategies for improving prognosis in breast cancer

Hosted by Ian Smith

The Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK

- **Ian Smith**
The Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK
Introduction
- **John Robertson**
University of Nottingham, UK
Auto-antibodies in breast cancer: a new diagnostic tool?
- **Stephen Johnston**
The Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK
Combined targeted therapies in breast cancer
- **Robert Coleman**
Weston Park Hospital, University of Sheffield, UK
Bone targeted therapy: modifying the soil to prevent metastatic seeding

Proffered paper presentations:

- **Jason S Carroll**
University Cancer Research UK; Cambridge Research Institute, Cambridge, UK
BACR/AstraZeneca Frank Rose Young Scientist Award
Understanding how pioneer factors regulate Oestrogen receptor function in breast cancer cells
- **Darran O'Connor**
University College Dublin, Ireland
The cocaine and amphetamine-regulated transcript (CART) is an independent prognostic factor in lymph node-negative breast cancer and predicts tamoxifen response
- **Neil Jelly**
University of Lincoln, UK
Anti-stem cell factor enhances the effect of Anthracycline and Taxane chemotherapy in chemoresistant breast cancer cell lines

Paediatric tumours

Hosted by Pamela Kearns

University of Birmingham, UK

- **Pamela Kearns**
University of Birmingham, UK
Introduction
- **Nick Goulden**
Royal Hospital for Children and University of Bristol, UK
Minimal residual disease in acute lymphoblastic leukaemia
- **Peter Ambros**
Children's Cancer Research Institute, Vienna, Austria
Genetics of neuroblastoma
- **Sue Burchill**
Leeds Institute of Molecular Medicine, St James's University Hospital, Leeds
The clinical impact of fusion genes in paediatric sarcomas

Proffered paper presentations:

- **Matthew Murray**
Medical Research Council Cancer Cell Unit, Cambridge, UK
Malignant germ cell tumours display conserved microRNA (miRNA) profiles resulting in global changes in expression of mRNA targets
- **Catriona Parker**
University of Manchester, UK
Significant improvement in the outcome of children with ALL: result of the international randomised ALLR3 study
- **Seema Alexander**
University of Lincoln, USA CR-UK Children's Cancer Group, Paterson Institute of Cancer Research, Manchester, UK
Rac2 and asparaginyl endopeptidase regulates invasion in pre-B acute lymphoblastic leukaemia

PET Imaging

Hosted by Paul Marsden

Guy's, King's and St Thomas' School of Medicine, London, UK

- **Paul Marsden**
Guy's, King's and St Thomas' School of Medicine, London, UK
Introduction
- **Sibylle Ziegler**
Technical University of Munich, Germany
Basic principles and instrumentation for positron emission tomography
- **Stefano Fanti**
University of Bologna, Policlinico, Italy
Positron emission tomography - but not fludeoxyglucose
- **Roland Haubner**
University of Innsbruck, Austria
Non-invasive tracer techniques to characterise angiogenesis

Proffered paper presentations:

- **Martin Christlieb**
CRUK-MRC Gray Institute for Radiation Oncology and Biology, University of Oxford, UK
Developments in imaging hypoxia: new tracers and data modelling

- **Catherine Kelly**
CRUK-MRC Gray Institute for Radiation Oncology and Biology, University of Oxford, UK
A method for quantifying the kinetics of hypoxia tracers using multicellular tumour spheroids
- **Rehan Ali**
CRUK-MRC Gray Institute for Radiation Oncology and Biology, University of Oxford, UK
Using mathematical modelling to gain new insights into how tumour cells respond to hypoxia-selective PET tracers

Proffered paper highlights 1

Hosted by Arnie Purushotham

King's College London, UK

- **Alison Young**
St James's Institute of Oncology, Leeds, UK
Factors influencing adjuvant treatment choices in stage I seminoma: the patients' perspective
- **Juliet Gray**
University of Southampton, UK
Combining peptide vaccination with immunostimulatory monoclonal antibodies provides potent immunotherapy in neuroblastoma
- **Victoria Coupland**
King's College London, UK
Does place of death from lung, colorectal, breast, and prostate cancer vary between ethnic groups?
- **Scott Morgan**
Institute of Cancer Research, Surrey, UK
Benefit of radiotherapy dose escalation in localised prostate cancer with respect to expression of intrinsic markers of hypoxia
- **Shahneen Sandhu**
Royal Marsden NHS Foundation Trust, Surrey, UK
Pharmacokinetic and pharmacodynamic Phase I trial of ARQ197 incorporating dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) studies investigating the antiangiogenic activity of selective c-Met inhibition
- **David Sebag-Montefiore**
On behalf of the National Cancer Research Institute and the 2nd Anal Cancer Trial Management Group, University College Clinical Trials Unit, London, UK
The second anal cancer trial (ACT2): a randomised trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin/5FU in squamous cell carcinoma of the anus
- **Paul Ghaneh**
Liverpool CR-UK Cancer Centre and Liverpool Cancer Trials Unit, UK
ESPAC-3(v2): a multicentre, international, open label, randomised controlled phase III trial of adjuvant 5-fluorouracil/folinic acid versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma

- **John Burn¹, John Mathers¹, Anne-Marie Gerdes¹, Marie-Luise Bisgaard², D Gareth Evans³, Diana Eccles⁴, Annika Lindblom⁵, Finlay Macrae⁶, Eamonn Maher⁷, Jukka-Pekka Mecklin⁸, Gabriela Moeslein⁹, Sylviane Olschwang¹⁰, Raj Ramesar¹¹, Hans Vasen¹², Juul Wijnen¹³, Gail Barker¹, Faye Elliott¹⁴, Henry Lynch¹⁵, D Timothy Bishop¹⁴**

¹Newcastle University, UK; ²University of Copenhagen, Denmark; ³St Mary's Hospital, Manchester, UK; ⁴University of Southampton, UK; ⁵Karolinska Hospital, Stockholm, Sweden; ⁶The Royal Melbourne Hospital, Melbourne, Australia; ⁷Birmingham Women's Hospital, UK; ⁸Jyväskylä Central Hospital, Finland; ⁹St. Josefs-Hospital Bochum-Linden, Germany; ¹⁰Institut Paoli Calmettes, Marseille, France; ¹¹University of Cape Town, South Africa; ¹²Foundation for Detection of Hereditary Tumours, Leiden, Netherlands; ¹³Leiden University Medical Center, Netherlands; ¹⁴University of Leeds, UK; ¹⁵Creighton University School of Medicine, Omaha, USA

CAPP2 long term follow up: aspirin protects against hereditary cancer

- **Discussion**

Targeting mitosis

Hosted by **Ashok Venkitaraman**

University of Cambridge, UK

- **Ashok Venkitaraman**
University of Cambridge, UK
Introduction
- **Andrea Musacchio**
IFOM-IEO Campus, Italy
Small molecule inhibitors of mitotic progression
- **Robert Wilkinson**
Astra Zeneca, UK
Probing the mechanism of novel drugs targeted to mitosis in pre-clinical studies
- **Johann de Bono**
The Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK
Early clinical studies with anti-mitotic agents

Proffered paper presentations:

- **Maria Thanasoula**
CRUK-MRC Gray Institute for Radiation Oncology and Biology, Oxford, UK
p53 prevents entry into mitosis with uncapped telomeres
- **Maciej A Kaliszczak**
Imperial College London, UK
Physicochemical and pharmacological determinants of the efficacy of a novel series of CDK7 inhibitors
- **Gareth Williams**
University College London, UK
Loss of a FOXO3A-dependent cell cycle checkpoint for DNA replication origins sensitises cancer cells to CDC7 inhibitors

Upper gastrointestinal cancers

Hosted by **David Cunningham¹** and **John Neoptolemos²**

¹Royal Marsden Hospital, Sutton, UK and ²University of Liverpool, UK

- **David Cunningham**
Royal Marsden Hospital, Sutton, UK
Introduction

- **Joerg Hoheisel**
German Cancer Research Center (DKFZ), Heidelberg, Germany
Functional genomics and proteomics in pancreatic cancer research
- **Krish Raganath**
Nottingham University Hospitals NHS Trust, UK
Evidence base of prevention in upper gastrointestinal cancer
- **Martyn Caplin**
The Royal Free Hospital, London, UK
Advances in the management of neuroendocrine tumours

Proffered paper presentations:

- **John Bridgewater**
University College London, UK
Gemcitabine with or without cisplatin in patients with advanced or metastatic biliary tract cancer (ABC): results of a multicentre, randomised phase III trial (the UK ABC-02 trial)
- **Rachael Barlow**
Cardiff University, UK
Randomised controlled trial of early enteral nutrition versus conventional management in patients undergoing major resection for upper gastrointestinal cancer
- **Nigel Jamieson**
University of Glasgow, UK
A microRNA prognostic signature for pancreatic ductal adenocarcinoma

Parallel sessions in detail **Tuesday**

Acute leukaemia

Hosted by Tony Green¹ and Tessa Holyoake²

¹University of Cambridge, UK; and ²University of Glasgow, UK

- **Tony Green¹ and Tessa Holyoake²**

¹University of Cambridge, UK; and ²University of Glasgow, UK

Introduction

- **Jan Cools**

University of Leuven, Belgium

Molecular genetics of T-cell acute lymphoblastic leukaemia

- **Charles Mullighan**

St Jude Children's Research Hospital, Memphis, USA

Genomic profiling of B-progenitor acute lymphoblastic leukaemia

- **Alan Burnett**

Cardiff University, UK

The impact of cytogenetic and molecular information on decision making in AML

Proffered paper presentations:

- **Shobha Kudva**

University of Manchester, UK

Prediction of HLA-DRB1-restricted CD4+ T cell epitopes in the childhood ALL-associated TEL-AML1 fusion oncoprotein: population coverage, and design of heteroclitic peptides

- **Kim Orchard**

SUHT, Southampton, UK

Targeted radiotherapy with an anti-CD66 monoclonal antibody prior to haematopoietic stem cell transplantation: therapy intensification without toxicity

- **Thomas Dunwell**

University of Birmingham, UK

Genome-wide epigenetic analysis of childhood acute lymphoblastic leukaemia

Anti-cancer drug discovery: natural products and rational design

Hosted by Ian Collins

The Institute of Cancer Research, Sutton, UK

- **Ian Collins**

The Institute of Cancer Research, Sutton, UK

Introduction

- **Nicolas Winssinger**

Université Louis Pasteur, Strasbourg, France

Diversity oriented synthesis based on natural product scaffolds

- **Barry Wilkinson**

Biotica, Cambridge, UK

Introduction Lead optimisation of rapamycin mTOR inhibitors through biosynthetic engineering

- **Mark Searcey**

School of Chemical Sciences & Pharmacy, University of East Anglia, UK

Design, synthesis and investigation of antitumour agents based on natural products

Proffered paper presentations:

- **CR Ireson**
Cancer Research Technology Discovery Laboratories, Wolfson Institute for Biomedical Research, London, UK
A novel small molecule inhibitor of protein kinase D blocks pancreatic cancer growth *in vivo*
- **Wolfgang Link**
Spanish National Cancer Centre (CNIO), Madrid, Spain
Image based pathway analysis of FOXO regulation leads to the discovery of therapeutic targets and small molecule inhibitors for anticancer therapy
- **Patrick Eyers**
University of Sheffield, London, UK
A biochemical and chemical genetic analysis of Aurora and Polo-like kinase inhibitors

Colorectal cancer: optimising screening and prevention

Hosted by Bob Steele

Ninewells Hospital and Medical School, Dundee, UK

- **Bob Steele**
Ninewells Hospital and Medical School, Dundee, UK
Introduction
- **Graeme Young**
Flinders University, Adelaide, Australia
Optimising population screening for colorectal cancer
- **Annie Anderson**
University of Dundee, UK
Colorectal cancer screening: an underdeveloped opportunity for promoting lifestyle change?
- **Richard Logan**
University of Nottingham, UK
Adenoma prevention trials - where next?

Proffered paper presentations:

- **Donald Maxwell Parkin**
Queen Mary, University of London, UK
The fraction of colorectal cancer attributable to lifestyle and environmental factors in the UK in 2005
- **Christian von Wagner**
University College London, London, UK
Inequalities in colorectal cancer screening participation: a neighbourhood- level analysis of inner and outer London areas
- **Taina Taskila**
Primary Care Clinical Sciences, University of Birmingham, UK
Factors affecting attitudes towards colorectal cancer screening in the primary care population



- **Andy Futreal**
Wellcome Trust Sanger Institute, Hinxton, UK
Introduction
- **Andy Futreal**
Wellcome Trust Sanger Institute, Hinxton, UK
Title to be confirmed
- **Bruno Clement**
Institut national de la santé et de la recherche médicale (INSERM), France
Hepatocellular cancer and genomes
- **Stacey Gabriel**
Broad Institute, Massachusetts Institute of Technology, Cambridge, USA
Comprehensive cancer genome characterisation by sequencing

Proffered paper presentations:

- **Tarek Abdel-Fatah**
School of Molecular Medical Sciences and Nottingham University Hospital Trust, University of Nottingham, UK
High resolution array Comparative Genomic Hybridization (aCGH) of breast carcinoma identifies Mouse Double Minutes 4 (Mdm4) as one of the early genetic changes in breast cancer development: Mdm4 is a new independent prognostic and predictive marker
- **Salwati Shuib**
School Department of Medical and Molecular Genetics, University of Birmingham, UK
Analysis of copy number alterations in familial and sporadic clear cell renal cell carcinoma with high resolution SNP arrays
- **Juliet Kenicer**
Edinburgh Cancer Research Centre, the University of Edinburgh, UK
A transcriptomic and genomic investigation into taxane resistant breast cancer

Proffered paper highlights 2

Host to be confirmed

- **Zuzana Bencokova**
CR-UK/MRC Gray Institute for Radiation Oncology and Biology, University of Oxford, UK
Sensitisation of hypoxic tumour cells through inhibition of PARP is oxygen dependent and correlates with decreased homologous recombination
- **Debbie Cunningham**
University of Birmingham, UK
Differential phosphoproteomics of fibroblast growth factor signalling: identification of Src-mediated phosphorylation events
- **Patricia Muller**
The Beatson Institute for Cancer Research, Glasgow, UK
Mutant p53 regulates invasion via integrins and EGFR
- **Gareth Inman**
The Beatson Institute for Cancer Research, Glasgow, UK
Downregulation of Disabled-2 switches TGF-beta from a tumour suppressor to a tumour promoter

- **Simon Gayther**
University Department of Gynaecological Oncology, UCL EGA Institute for Women's Health, University College London, London, UK
A genome-wide association study identifies a novel ovarian cancer susceptibility locus on chromosome 9p22
- **Joan Kyula**
Queen's University, Belfast, UK
ADAM-17 is a key regulator of ErbB survival response in colorectal cancer
- **NingNing Li**
University of Nottingham, UK
Fbxw7 (hCDC4) E3- Ubiquitin Ligase Receptor: lineage potential and its commitment to cancer

Prostate and bladder cancer

Hosted by Noel Clarke

Christie NHS Foundation Trust, Manchester, UK

- **Noel Clarke**
University of Manchester, UK
Introduction
- **Freddie Hamdy**
University of Oxford, UK
Screening for prostate cancer
- **David Dearnaley**
The Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK
The management of high risk localised prostate cancer
- **Vijay Ramani**
Christie NHS Foundation Trust, Manchester, UK
Surgical and oncological outcomes following cystectomy for transitional cell cancer
- **Richard Cowan**
Christie NHS Foundation Trust, Manchester, UK
Techniques for bladder preservation for muscle invasive bladder cancer
- **Gert Attard**
Drug Development Unit, Institute of Cancer Research, Royal Marsden Hospital, Surrey, UK
ACP McElwain Prize: Castration-Resistant Prostate Cancer (CRPC)

Proffered paper presentations:

- **Imran Ahmad**
Beatson Institute for Cancer Research, Glasgow, UK
FGFR3 mutation is not the initiating mutation in urothelial cell cancer
- **Ros Eeles**
The Institute of Cancer Research, Sutton, Surrey, UK
Identification of multiple genetic variants which predispose to prostate cancer by genome-wide association in the PRACTICAL international consortium



ProstateResearch
PROSTATE CANCER RESEARCH FOUNDATION

Radiation oncology

Hosted by Gillies McKenna

Gray Institute for Radiation Oncology and Biology, Oxford, UK

- **Gillies McKenna**
Gray Institute for Radiation Oncology and Biology, Oxford, UK
Introduction
- **Kaye Williams**
University of Manchester, UK
Hypoxic targets for radiotherapy
- **Ruth Muschel**
University of Oxford, UK
Utilisation of the pre-existing vessels in cancer metastasis
- **John Humm**
Memorial Sloan-Kettering Cancer Center, New York, USA
Imaging the tumour microenvironment by PET

Proffered paper presentations:

- **Sebastian Serres**
University of Oxford, UK
Early detection of brain metastasis using novel MRI contrast agent targeting VCAM-1
- **Veerle Kersemans**
Gray Institute for Radiation Oncology and Biology, Oxford, UK
Micro-CT imaging for anatomical referencing in PET and SPECT: radiation dose, biological damage and image quality
- **Katherine Vallis**
University of Oxford, Gray Institute for Radiation Oncology and Biology, UK
 γ H2AX: a target for imaging and systemic radiation therapy

Research portrayal in the media

Hosted by Frances Balkwill

Bart's and The London School of Medicine and Dentistry, UK

- **Frances Balkwill**
Bart's and The London School of Medicine and Dentistry, UK
Introduction
- **Nicholas Hillier**
The Academy of Medical Sciences, London, UK
Hype, hope and hybrids: science, policy and media perspectives of the Human Fertilisation and Embryology Bill
- **Geoff Watts**
Freelance science and medical writer and broadcaster, UK
Seeing things from both sides
- **Ruth Francis**
Nature Publishing Group, London, UK
Research portrayal in the media – translation from abstract to media
- **Sara Candy**
Wellcome Trust, London, UK
The Wellcome Monitor of public awareness, knowledge, interest and attitudes to biomedical science
- **Discussion**

Senescence and autophagy as an approach to therapy

Hosted by Sharon Tooze

Cancer Research UK London Research Institute, UK

- **Sharon Tooze**
Cancer Research UK London Research Institute, UK
Introduction
- **Kevin Ryan**
Beatson Institute for Cancer Research, Glasgow, UK
Autophagy in the control of tumour cell death
- **Marja Jäättelä**
Danish Cancer Society, Institute of Cancer Biology, Copenhagen, Denmark
Lysosomal involvement in cell death and cancer
- **John Cleveland**
Scripps Research Institute, Jupiter, Florida, USA
The role of the autophagy pathway in the development and maintenance of Myc-driven lymphoma
- **Masashi Narita**
Cancer Research UK London Research Institute, UK
Autophagy in oncogene-induced senescence

Proffered paper presentations:

- **Madhu Basetti**
Cancer Research UK Cambridge Research Institute, Cambridge, UK
Choline metabolism in cellular senescence, quiescence and transformation: a 1H NMR based metabolomics study
- **Patricia Roxburgh**
The Beatson Institute for Cancer Research, Glasgow, UK
Inhibition of MDM2: a safe strategy in the presence of mutant p53
- **Owen Sansom**
The Beatson Institute for Cancer Research, Glasgow, UK
 β -Catenin induced senescence progresses to urothelial cell carcinoma with PTEN mutation

Survivorship and late effects of treatment

Hosted by Jane Maher

Macmillan Cancer Support, UK

- **Jane Maher**
Macmillan Cancer Support, UK
Introduction
- **Flora Van Leeuwen**
Netherlands Cancer Institute, The Netherlands
Second malignancy after chemotherapy and radiotherapy
- **Gill Levitt**
Great Ormond Street Hospital, London, UK
Chronic illness after cancer treatment: lessons from childhood cancer survivors
- **Craig Earle**
Dana-Farber Cancer Institute, Boston, USA
Caring for cancer survivors

Proffered paper presentations:

- **Farhad Mashayekhi**
Islamic Azad University, Tonekabon, Iran, Islamic Republic of
An immunohistochemical study of eukaryotic initiation factor (eIF4E) expression in brain tumour

**WE ARE
MACMILLAN.
CANCER SUPPORT**

- **Michelle McRobbie**
University of Oxford, UK
Genetic pathways for the prediction of the effects of ionising radiation: low dose radiosensitivity and risk to normal tissue after radiotherapy
- **Nada Khan**
University of Oxford, UK
Late effects associated with treatments for breast, colorectal and prostate cancer: a matched cohort study using the General Practice Research Database and National Cancer Intelligence Network

Parallel sessions in detail **Wednesday**

Brain tumours

Hosted by Susan Short

University College Hospital, London, UK

- **Susan Short**
University College Hospital, London, UK
Introduction
- **Rossella Galli**
Stem cell Research Institute, Milan, Italy
Functional and molecular characterisation of cancer stem cells from brain tumours
- **Walter Stummer**
University of Dusseldorf, Germany
Issues in the surgical therapy of malignant gliomas
- **Anca Grosu**
University of Freiburg, Germany
PET imaging and glioma

Proffered paper presentations:

- **Talal Fael Al-Mayhani**
University of Cambridge, UK
NG2 expression identifies a cell population capable of maintaining tumour growth in glioblastoma
- **Simone Wilkins**
University of Liverpool, UK
Vascularity in regions of highest choline predicts progression in low grade astrocytomas
- **Mausam Singhera**
University College London, UK
Outcome in a 2-year cohort of brain metastases patients treated in a specialist multi-disciplinary clinic at UCLH

Economics of drug development and provision

Hosted by Sir Kenneth Calman¹ and David Ardron²

¹University of Glasgow, UK; and ²NCRI Consumer Liaison Group

- **Sir Kenneth Calman¹ and David Ardron²**
¹University of Glasgow, UK; and ²NCRI Consumer Liaison Group, UK
Introduction
- **Alison Clough**
The Association of the British Pharmaceutical Industry, London, UK
Life and medicines: price and value
- **Elisabeth George**
National Institute for Health and Clinical Excellence, London, UK
Appraising cancer drugs at the National Institute for Clinical and Health Excellence
- **David Gillen**
Pfizer, UK
The challenge for the pharmaceutical industry in the 21st century: discovery, development and access to medicines in a distrustful environment
- **Martin Gore**
The Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK
Title to be confirmed

Proffered paper presentations:

- **Timothy Yap**
Royal Marsden Hospital, Sutton, UK
First-in-man, first-in-class, pharmacokinetic and pharmacodynamic phase I clinical trial of a human monoclonal antibody CNTO888 to CC-Chemokine Ligand 2 (CCL2/MCP-1) in patients with advance solid tumours
- **David Blakey**
AstraZeneca, Macclesfield, UK
Identification of a human antibody 3.19.3 that inhibits ANG-2 function leading to significant anti-tumour activity, both alone and in combination with VEGF inhibitors, in a panel of tumour xenograft models
- **Barbara Delage**
Institute of Cancer, Barts and the London, London, UK
Novel anticancer drug combinations exploiting arginine depletion with ADI-PEG 20 in the treatment of ASS1-negative malignant mesothelioma
- **Discussion**

Personalised pathology

Hosted by Philip Quirke

University of Leeds, UK

- **Philip Quirke**
University of Leeds, UK
Introduction
- **Alberto Bardelli**
University of Turin, Italy
Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer
- **Tim Maughan**
Cardiff University, UK
Molecular selection of therapy in colorectal cancer: COIN and FOCUS 3 trials
- **Susan Richman**
University of Leeds, UK
Prognostic and predictive value of KRAS and BRAF mutation status and its heterogeneous nature in aCRC
- **Adrian Jubb**
University of Oxford, UK
Predicting benefit from anti-VEGF therapy

Proffered paper presentations:

- **Carol Walker**
School of Cancer Studies, Liverpool, UK
Prognostic significance of MGMT promoter methylation in glioblastomas treated with temozolomide and radiotherapy
- **Gillian Smith**
University of Dundee, Scotland, UK
Novel mutations in the K-Ras oncogene: implications for personalised medicine in the treatment of colorectal cancer

- **Steven Walker**
Almac Diagnostics, Northern Ireland, UK
The detailed molecular analysis of formalin-fixed paraffin embedded (FFPE) wild-type or mutant KRAS colorectal primaries with the aims of identifying transcripts and pathways of relevance to Cetuximab sensitivity and/or KRAS mutational status

Preclinical models

Hosted by Alan Clarke

Cardiff University, UK

- **Alan Clarke**
Cardiff University, UK
Introduction
- **Jos Jonkers**
Netherlands Cancer Institute, Amsterdam, The Netherlands
Preclinical models of mammary cancer
- **Bart Vanhaesebroeck**
Barts and The London School of Medicine, London, UK
Preclinical dissection of the phosphoinositide 3-kinase pathway
- **Gerard Evan**
UCSF Helen Diller Family Comprehensive Cancer Centre, San Francisco, USA
Dissecting the tumours and its microenvironment *in vivo*

Proffered paper presentations:

- **Min Li**
Baylor College of Medicine, Houston, Texas, USA
Spindle assembly checkpoint, chromosomal instability, and cancer
- **Owen Sansom**
The Beatson Institute, Glasgow, UK
Crypt stem cells as the cells-of-origin of intestinal cancer
- **Qi Zeng**
Institute of Molecular and Cell Biology, Singapore
Monoclonal antibodies target intracellular PRL phosphatases to inhibit cancer metastases in mice



Raising awareness and promoting early diagnosis

Hosted by Amanda Ramirez

Guy's, King's and St Thomas' School of Medicine, London, UK

- **Amanda Ramirez**
Guy's, King's and St Thomas' School of Medicine, London, UK
Introduction
- **David Lyon**
Castlefields Health Centre, Runcorn, UK
Healthy communities collaborative: a community-based intervention to promote early presentation of cancer
- **Jane Wardle**
University College London, UK
Measuring public awareness of cancer
- **Lindsay Forbes**
Guy's, King's and St Thomas' School of Medicine, London, UK
A health professional-delivered one-to-one intervention to promote early presentation in breast cancer: a randomised controlled trial



Proffered paper presentation:

- **Ruth Jack**
King's College London, UK
Breast cancer incidence, treatment and survival in ethnic groups in South East England
- **Lindsay Forbes**
Guy's, King's and St Thomas' School of Medicine, London, UK
A systematic review of interventions to increase cancer awareness and promote early presentation
- **Discussion**

Showcasing the successes from the ECMC Network: early phase trials, biomarkers and imaging

Hosted by Sally Burtles

Cancer Research UK, UK

- **Sally Burtles**
Cancer Research UK, UK
Introduction
- **Udai Banerji**
The Institute of Cancer Research, UK
Showcasing The Institute of Cancer Research and The Royal Marsden Experimental Cancer Medicine Centre
- **James Brenton**
Cancer Research UK Cambridge Research Institute, UK
Showcasing the Cambridge Experimental Cancer Medicine Centre
- **Christian Ottensmeier**
University of Southampton, UK
Showcasing the Southampton Experimental Cancer Medicine Centre
- **Will Steward**
University of Leicester, UK
Showcasing the Leicester Experimental Cancer Medicine Centre
- **Dion Morton**
University of Birmingham, UK
Showcasing the Birmingham Experimental Cancer Medicine Centre
- **Alan Burnett**
University of Cardiff, UK
Showcasing the Cardiff Experimental Cancer Medicine Centre
- **Tim Illidge**
University of Manchester, UK
Showcasing the Manchester Experimental Cancer Medicine Centre

Symptom management

Hosted by Mike Bennett

University of Lancaster, UK

- **Mike Bennett**
University of Lancaster, UK
Introduction

- **Mike Bennett**
University of Lancaster, UK
Patient-based educational interventions: evidence and implementation
- **Stein Kaasa**
Norwegian University of Science & Technology, Trondheim, Norway
Assessing cancer pain with new technologies
- **Joanne Droney**
St Joseph's Hospice, London, UK
Impact of pharmacogenomics on cancer pain management

Proffered paper presentations:

- **Linda Sharp**
National Cancer Registry Ireland, Cork, Ireland
Associations between the financial impact of cancer and depression, anxiety and stress in individuals with breast, lung and prostate cancer
- **Jane B Hopkinson**
University of Southampton, UK
A feasibility study: a mixed methods exploratory phase II cluster randomised trial to investigate the effectiveness of the 'Macmillan Approach to Weight loss and Eating difficulties' (MAWE)
- **Alan O'Kane**
Ninewells Hospital, Dundee, UK
Assessing the effects of implementing the MASCC (Multinational Association of Supportive Care in Cancer) Antiemetic Guideline on the severity of nausea and vomiting following platinum chemotherapy

Synthetic lethality: targeting damaged pathways

Hosted by Thomas Helleday

CRUK-MRC Gray Institute for Radiation Oncology and Biology, University of Oxford, UK

- **Thomas Helleday**
CRUK- MRC Gray Institute for Radiation Oncology and Biology, University of Oxford, UK
Introduction
- **Thomas Helleday**
University of Oxford, UK
Exploiting synthetic lethality in DNA repair for cancer therapy
- **Toshiyasu Taniguchi**
Fred Hutchinson Cancer Research Center, USA
Secondary mutation of BRCA1/2 as a mechanism of drug resistance in BRCA1/2-mutated cancer
- **Ester Hammond**
University of Oxford, UK
Exploiting hypoxia for anti-cancer therapy using a synthetic context lethality approach

Proffered paper presentations:

- **Madeleine Hewish**
Institute of Cancer Research, London, UK
Complementary RNA interference and compound screens to identify novel therapeutic targets for mismatch repair deficient cancers
- **Sarah Martin**
Institute of Cancer Research, London, UK
DNA polymerases as potential therapeutic targets for DNA mismatch repair deficient cancers
- **Mohammed Mohammed**
University of Nottingham, UK
Development of human apurinic/apyrimidinic endonuclease (APE1) inhibitors for cancer therapy

Tumour stroma and vasculature

Hosted by Clare Isacke

Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK

- **Clare Isacke**
Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK
Introduction
- **Janine Erler**
The Institute of Cancer Research, London, UK
Exploring hypoxia-mediated tumour progression
BACR Translational Research Award
- **Luigi Naldini**
Vita-Salute San Raffaele University, Milan, Italy
New effectors and therapeutic targets in the tumour-stroma interaction
- **William Stallcup**
Burnham Institute for Medical Research, La Jolla, USA
NG2 proteoglycan in tumour vascularisation and progression

Proffered paper presentations:

- **Jae Hong Im**
CRUK- MRC Gray Institute for Radiation Oncology and Biology, University of Oxford, UK
Vascular response during metastasis is organ-specific and regulated by host angiopoietin-2
- **Hagen Kulbe**
Institute of Cancer, London, UK
The chemokine receptor CXCR4 and its ligand CXCL12 sustain a cell-autonomous network in ovarian cancer
- **Abigail Welford**
University of Sheffield, UK
Macrophages and tumour revascularisation following treatment with vascular disrupting agents

Workshops & debates in detail **Sunday**

The tumour microenvironment and its effect on treatment response: The Cancer Recognised Research Group in Northern Ireland (CRRG) Workshop

12.15 – 14.15

Hosted by **Stephanie McKeown** and **Tracy Robson**

The Cancer Recognised Research Group (CRRG) in Northern Ireland Workshop is funded and sponsored by the Northern Ireland R&D office. Its main purpose is to highlight the cancer research effort in Northern Ireland through presentations by young investigators in key research areas.

- **Margaret Ashcroft**

Department of Translational Medicine and Therapeutics, University College London, UK

Targeting the HIF pathway as a therapeutic approach to cancer

- **Louise Ming, Maxwell Omabe, Christopher A Mitchell, Jenny Worthington, Stephanie R McKeown**

Biomedical Science Research Institute, University of Ulster, Coleraine, Northern Ireland, UK

Does hypoxia play a role in the failure of androgen ablation therapy for prostate cancer?

- **Anita Yakkundi¹, Andrea Valentine¹, Martin O'Rourke¹, Michelle Hookham¹, Hayder Dyer¹, David Waugh², Tim Harrison³, Ian James³, Graham Cotton³, David Hirst¹, Tracy Robson¹**

¹School of Pharmacy, Queen's University Belfast, Northern Ireland, UK;

²Centre for Cancer Research and Cell Biology, Queen's University Belfast, Northern Ireland, UK; ³Almac Discovery, Craigavon, Northern Ireland, UK

FKBPL and its 24mer peptide derivative inhibit angiogenesis and metastases by targeting CD44

- **Philip Dunne¹, Jennifer R McDaid¹, Jayne Loughery¹, Jayne C Boyer², C Stephen Downes¹, Rosann A Farber² and Colum P Walsh¹**

¹School of Biomedical Sciences, University of Ulster, Northern Ireland, UK;

²Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, North Carolina, USA

MLH1 mediates PARP-dependent cell death in response to the methylating agent N-methyl-N-nitrosourea

- **Nyree Crawford, Keara Redmond, Niamh Buckley, Paul Mullan**

Centre for Cancer Research and Cell Biology, Queen's University, Belfast, Northern Ireland, UK

TBX2 drives the proliferation of breast cancer cells through repression of an EGR1-dependent signalling program

Workshops & debates in detail **Monday**

BACR educational workshop: early phase clinical trial design for non-clinicians

08.00 – 08.50

Hosted by Anne Thomas

University of Leicester, UK

- **Bruno Morgan**

University of Leicester, UK

Introducing imaging biomarkers into clinical studies

Bruno Morgan will give a broad overview of the difficulties of introducing imaging biomarkers into clinical studies, with examples of successes and failures, ethical considerations, data problems and consistency.

- **Anne Thomas**

University of Leicester, UK

Pragmatic design of phase I clinical studies

Anne Thomas will then focus on the practicalities of tissue and blood sampling from the patients; nurse and ethics committee perspective.

BOA 'Meet the Professor' workshop: cell cycle control, mechanisms and their relevance to cancer?

08.00 – 08.50

Hosted by Kai Stoeber

University College London, UK

Illumina high throughput sequencing: investigations into cancer genome biology

13.00 – 14.00

Hosted by Illumina

This seminar will include two talks from customers using the Genome Analyzer Next Generation Sequencer showing the latest applications relevant to cancer research - examples could include mRNA-seq, ChIP-seq, small RNA, genome sequencing for rearrangements/gene fusions, methylation sequencing. There will also be a talk from an Illumina representative sharing the workflow and capability of the system and the latest roadmap of output and applications for 2009.



Emerging treatment options in metastatic disease

13.00 – 14.00

Hosted by Amgen

Metastatic disease represents a large patient population. Common tumours include breast and colorectal cancer. We are presenting important data in both KRAS wild type colorectal cancer patients receiving first and second line chemotherapy combined with Panitumumab and Denosumab, a RANK ligand inhibitor, in breast cancer patients with bone metastases.

Randomised phase 3 study of Panitumumab with FOLFOX compared to FOLFOX alone as first-line treatment for metastatic colorectal cancer

Speaker to be confirmed

Randomised phase 3 study of Panitumumab with FOLFIRI compared FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer

Marc Peeters, University Hospital Ghent, Belgium

Randomised phase 3 study of Denosumab compared to Zoledronic Acid in the Treatment of Bone Metastases in patients with Breast Cancer

Speaker to be confirmed



How to become a post-doc or a clinician scientist

14.30 – 15.30

Hosted by Sally Leever¹, Guillermina Lozano², Bart Vanhaesebroeck³ and Charlie Swanton¹

¹Cancer Research UK London Research Institute, UK; ²MD Anderson Center, Houston, USA; ³Barts and The London School of Medicine, London, UK

Securing 'the right' postdoc position to go to after your PhD, is an important next step in your scientific career and can be a daunting task! This workshop will explore the various issues to think about when choosing potential labs to postdoc in, as well as providing advice on how to go about getting the position that you want! The issues discussed should be relevant to PhD students doing non-clinical PhDs and to clinical fellows considering clinician scientist positions.

Prioritising research in the networks

14.30 – 15.30

Hosted by David Cameron

National Cancer Research Network, UK

This workshop will look at the role of the National Cancer Research Network (NCRN) in clinical cancer research in the UK. The NCRN is part of the NHS National Institute for Health Research: a Department of Health funded virtual enterprise dedicated to establishing the NHS as an internationally recognised centre of research excellence. Being part of this large family of clinical research networks and research funders brings big advantages and some responsibilities, and we will discuss how this affects individual researchers.

In particular, we will focus on the following areas:

1. How to ensure your research project is eligible for access to NCRN and other NHS resources
2. How NCRN/NCRI prioritises research nationally
3. How local networks prioritise which research they will do
4. Latest information from the Department of Health about how research costs are covered in terms of what needs to come from the research grant and what can be covered in the NHS/NCRN

Randomised controlled trials in end of life care

14.30 – 15.30

Hosted by Anthony Byrne¹ and Gary Young²

¹Marie Curie Hospice and Wales Cancer Trials Unit, Penarth, UK; ²TBC



The randomised controlled trial has been championed as a 'gold standard' provider of evidence for assimilation into evidence-based practice. This has had a strong influence on the development of clinical guidelines and commissioning of care. Such an approach has been challenged in the context of evaluating complex interventions and in settings where trials conduct is challenging.

This workshop will explore and debate the role of the randomised controlled trial in the palliative care setting. In particular it will focus on:

1. The challenge of evidence: specifically the grades of reliability of research evidence required for guideline development and commissioning of treatment.
2. The methodological and trials conduct opportunities to respond to those challenges using the RCT model in palliative and end of life care.
3. The importance of pragmatic and meaningful outcomes which directly reflect patient benefit in this setting.

The workshop will take account of previous experience of RCTs in palliative care settings and refer to the current NIHR palliative care portfolio. Following the

presentations, the workshop will be opened to the floor for discussion.

Speakers/panel include:

Dr Fergus Macbeth, Director of the Centre for Clinical Practice, National Institute for Health and Clinical Excellence (NICE), UK

Professor Jane Blazeby, Professor of Surgery and Director of the MRC ConDuCT methodology hub, University of Bristol, UK

Professor Ian Tannock, Daniel E Bergsagel Professor of Medical Oncology, University of Toronto, Canada

Tumour banking and access to samples debate

14.30 – 15.30

Hosted by Philip Quirke

University of Leeds, UK



Workshops & debates in detail **Tuesday**

Novel practical designs for clinical trials

07.55-08.55

Hosted by Rhian Gabe

Medical Research Council Clinical Trials Unit, London, UK

- **Marc Buyse**
International Drug Development Institute Inc, Massachusetts, USA
Randomised phase II trials: are they really better?
- **Andrew Stone**
AstraZeneca, UK
Latest developments in phase II design
- **Mahesh Parmar**
Medical Research Council Clinical Trials Unit, London UK
Multi-arm, multi-stage clinical trial designs

BACR educational workshop: how do cells maintain their integrity? An introduction to DNA double strand break repair and its relevance to leukaemia

08.00-08.50

Hosted by Elaine Willmore

Northern Institute for Cancer Research, University of Newcastle upon Tyne, London, UK

Double strand breaks in DNA are potentially lethal. Cells have many ways of responding to insults to their DNA, from signalling pathways that tell the cell that DNA damage has happened, to activation of repair proteins to help restore the DNA. Often these repair pathways become dysfunctional, and this can lead to the genomic instability that is a hallmark of cancer cells.

Elaine Willmore will explain the basics of one of the fast components of double strand break repair (non homologous end joining), and describe some of the alterations in this pathway that occur in chronic and acute leukaemia. Claire Seedhouse (Nottingham University) will describe another double strand repair pathway (homologous recombinational repair) and explain how changes of activity of proteins in this pathway contribute to drug resistance in acute myeloid leukaemia.

BOA Workshop: all about 'omics

08.00-08.50

Hosted by the British Oncological Association

Methodologies in complementary therapy research

08.00-08.50

Hosted by Andrew Ritchie

NCRI Complementary Therapy Clinical Studies Development Group, London, UK

This 'how to' workshop session has been structured to engage and introduce laboratory scientists and oncologists to the field of complementary therapy research, highlight where conventional 'robust' methodologies may and may not be appropriate, give an overview of challenges associated with this research and show where successful studies have been funded and published.

- **Andrew Ritchie**
NCRI Complementary Therapy Clinical Studies Development Group, London
UK
Introduction
- **Dr Andrew Vickers**
Memorial Sloan-Kettering Cancer Centre, USA
Complementary therapies for symptom control in cancer patients:
the Memorial Sloan-Kettering Cancer Center Experience
- **Charlotte Patterson**
Universities of Exeter and Plymouth, UK
The development of patient centred and individualised outcome
measures and their use in complementary medicine research in
the field of cancer
- **Professor Alex Molassiotis**
University of Manchester, UK
Title to be confirmed

nab™ technology : advancing the treatment of breast cancer

12.30 – 14.00

Hosted by Abraxis Bioscience



International breast cancer experts will review the current breast cancer treatment landscape including novel taxanes and their impact in the management of metastatic breast cancer patients. Additionally, the faculty panel will discuss and present relevant clinical case studies that focus on current treatment management challenges in daily practice.

Agenda:

Introduction

Taxanes in the treatment of metastatic breast cancer

Improving clinical outcomes in metastatic breast cancer

Clinical case studies in metastatic breast cancer

Panel discussion

Learning objectives:

- Review current treatments in metastatic breast cancer
- Discuss novel taxanes for the treatment of metastatic breast cancer
- Discuss the management of metastatic breast cancer through case study reviews

Translating genomic biomarkers to medical advantage: the integrated genomics approach

13.00 – 14.00

Hosted by Affymetrix



The ability to interrogate the human genome using whole-genome analysis tools, such as microarrays, has altered and enhanced our approach to studying complex diseases such as cancer. Combining genomic information such as gene expression and gene regulation with genotype and copy number data has proven to be an effective means of achieving focused discovery and faster validation in cancer studies. Leading scientists and clinical researchers are increasingly using Affymetrix' integrated microarray solutions, which include the GeneChip Exon 1.0 ST, SNP 6.0 and miRNA arrays to facilitate their path from biomarker discovery to medical utility.

This workshop will help you as a research scientist, clinical researcher, or clinician to understand how scientists at the cutting edge of cancer research are successfully applying Affymetrix technology to accelerate their integrated genomics studies. You will also hear how their discoveries are being translated to powerful medical tools that positively impact the care and treatment of cancer.

Lunch and refreshments will be provided.

More information available from: <http://www.affx.com/forms/NCRiworkshop>

Improving clinical outcomes: focus on venous thromboembolism

13.00 – 14.00

Hosted by Annie Young¹ and Ajay Kakkar²

¹3 Counties Cancer Network, Gloucestershire, Herefordshire and South Worcestershire; UK Oncology Nurse Society ²Barts and the London School of Medicine and Dentistry; Thrombosis Research Institute, London, UK

Venous thromboembolism (VTE) is a condition that encompasses deep vein thrombosis (DVT) and pulmonary embolism (PE). Among patients who survive, VTE is associated with significant long-term complications (eg, recurrent VTE, postthrombotic syndrome, chronic leg ulcers, and chronic thromboembolic pulmonary hypertension).

Guidelines from the American Society of Clinical Oncology and the European Society of Medical Oncology recommend a proactive approach to VTE management in oncology patients. There is now a significant window of opportunity for this situation to improve, as our understanding of the risk factors for VTE, preventative modalities, and treatment of VTE has grown. Although some limitations remain to be overcome with current assessment, prevention, and treatment paradigms, even full institution of current, evidence-based, guideline-recommended modalities would substantially reduce the burden of VTE on patients, providers, and society.

In this highly interactive educational workshop utilizing audience response system technology and clinical cases, recognized experts will be invited to provide a fairbalanced, evidence-based review of recent landmarks in our understanding of the genesis of VTE, the pathophysiologic progression of disease from triggering events to long-term complications, diagnostic modalities, and recent evidence from clinical trials that support a proactive approach to disease avoidance.

The workshop will be of interest to oncologists, oncology pharmacists, oncology nurses and other healthcare professionals involved in the care of patients at risk for venous thromboembolism.

- **Annie Young**
3 Counties Cancer Network, Gloucestershire, Herefordshire and South Worcestershire; UK Oncology Nurse Society; UK
Welcome and introduction
- **Ajay Kakkar**
Barts and the London School of Medicine and Dentistry, London, UK; Thrombosis Research Institute, London, UK
Prevention of venous thromboembolism in the medical and surgical oncology patient
- **Annie Young**
3 Counties Cancer Network, Gloucestershire, Herefordshire and South Worcestershire; UK Oncology Nurse Society; UK
Treatment and secondary prevention of venous thromboembolism in cancer
- **Panel: interactive clinical case conference**
Moderated by Annie Young, Ajay Kakkar, Robert Coleman and others to be confirmed.

Career paths for post-docs

14.30 – 15.30

Hosted by Ian Gane

Roche Pharmaceuticals, UK

Following the highly successful Post Doc Careers Session held at the Conference in 2007, we are pleased to announce that the NCRI Industry Consultation Group will again host an interactive careers workshop at this year's Conference.

Ian Gane from Roche Pharmaceuticals will host the session, which will feature a variety of commercial career paths for post-docs including:

1. Clinical Research and Development
2. Drug Discovery & Pre-Clinical Research and Development
3. Marketing and Sales
4. Policy and Information
5. Medical/Scientific Affairs and Outcomes Research

Data linkage and long-term follow up of clinical trials

14.30-15.30

Hosted by David Forman¹ and David Cameron²

¹National Cancer Intelligence Network (NCIN), UK; ²National Cancer Research Network (NCRN), UK

The long-term follow-up of patients recruited into clinical trials is of enormous value in understanding the late consequences of treatment. This is, however, a time consuming and resource intensive process when carried out by trials offices on a trial by trial basis.

This Workshop will consider how linkage between clinical trial patient datasets and routine NHS data sources held within the NCIN National Cancer Data Repository offers the potential to provide such follow-up in a rapid and cost efficient manner. Results from early pilots using this process, including the MRC CLASICC and CR07 studies, will be presented together with protocols for the iBreast and other similar trials.

The Targeted Therapies Nurses Forum

14.30 – 15.30

Hosted by Lynette Lane¹ and Lynda Pyle²

¹Velindre Cancer Centre, Cardiff, UK; and ²Royal Marsden Hospital, London, UK

This workshop aims to highlight common side effects and their management for patients receiving targeted therapies, focusing on those drugs used in renal and gastrointestinal stromal tumour (GIST) cancers.

These drugs are extending peoples lives and have altered patients' outlook and life expectations. Using Maslow's theory on hierarchy of needs, we aim to develop a nursing tool, to enhance patients' quality of life.

- **Lynette Lane**

Velindre Cancer Centre, Cardiff, UK

Introduction

Breakout groups

Each table will discuss one of the following side effects:

1. Skin
2. Fatigue
3. GI disturbances
4. Hypertension and hypothyroidism
5. Compliance, expectations and attitudes to taking oral therapies

- **Linda Pyle**

Royal Marsden Hospital, London, UK

Discussion, feedback and summary